Compare Edwards Lifesciences Corporation Common Stock (EW) vs Norwegian Cruise Line Holdings Ltd (NCLH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Edwards Lifesciences Corporation Common Stock vs Norwegian Cruise Line Holdings Ltd — how do they compare? Edwards Lifesciences Corporation Common Stock trades at $84.25 (market cap $48.56B), while Norwegian Cruise Line Holdings Ltd trades at $15.58 (market cap $7.11B). The key difference: Edwards Lifesciences Corporation Common Stock is far larger — about 6.8× Norwegian Cruise Line Holdings Ltd's market cap, and Edwards Lifesciences Corporation Common Stock is trading nearer its 52-week high, Norwegian Cruise Line Holdings Ltd nearer its low. Which is the better fit depends on your goals.
| EW | NCLH | |
|---|---|---|
Market Cap | $48.56B | $7.11B |
Volume | 6,520,488 | 22,683,268 |
Sector | Health | Consumer Cyclical |
52-Week High | $95.18 | $25.02 |
52-Week Low | $72.65 | $14.12 |
Enterprise Value | $45.01B | $21.93B |
Typical Hold Time | — | 68 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Norwegian Cruise Line Holdings (NCLH) trades at $15.05, down 2.97% today, with neutral technical signals and strong analyst support. The company shows improving fundamentals with revenue growth from $9.5B in 2024 to $9.83B in 2025, though net income declined to $423M. Recent Q2 2026 earnings beat expectations at $0.48 EPS versus $0.41 expected, while management expects Q3 results to exceed guidance. Valuation remains attractive with P/E of 9.12 and P/S of 0.72.
NCLH presents a compelling value opportunity with analyst consensus price target of $20.86 offering 38% upside potential. However, investors face risks from persistent yield pressure, high debt levels ($11.78B long-term), and Caribbean pricing competition. The stock's outlook depends on successful execution of earlier booking strategies and maintaining EBITDA growth amid industry headwinds through 2027.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Edwards Lifesciences Corporation Common Stock
Edwards Lifesciences develops medical technologies for structural heart disease. Its products include transcatheter aortic-valve replacement, mitral and tricuspid therapies, and surgical structural-heart technologies.
Read more on EW →About Norwegian Cruise Line Holdings Ltd
Norwegian Cruise Line is the world's third-largest cruise company by berths (at more than 62,000), operating 29 ships across three brands (Norwegian, Oceania, and Regent Seven Seas), offering both freestyle and luxury cruising. The company has redeployed its entire fleet as of May 2022. With eight passenger vessels on order among its brands through 2027 (representing 20,000 incremental berths), Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sailed to around 500 global destinations before the pandemic.
Read more on NCLH →
